截至9月30日，益诺思股东户数4849.00，较上期减少9.97%；人均流通股18703股，较上期增加 257.28%。2025年1月-9月，益诺思实现营业收入5.71亿元，同比减少35.33%；归母净利润-1478.81万 元，同比减少111.14%。 1月7日，益诺思涨20.00%，成交额3.17亿元。两融数据显示，当日益诺思获融资买入额7343.23万元， 融资偿还2250.89万元，融资净买入5092.34万元。截至1月7日，益诺思融资融券余额合计1.11亿元。 分红方面，益诺思A股上市后累计派现4511.35万元。 融资方面，益诺思当日融资买入7343.23万元。当前融资余额1.11亿元，占流通市值的2.21%，融资余额 超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，益诺思十大流通股东中，汇添富医药保健混合（470006）位居第 九大流通股东，持股112.15万股，为新进股东。华夏稳盛混合（005450）位居第十大流通股东，持股 93.05万股，为新进股东。工银医疗保健股票（000831）、工银战略转型股票A（000991）、嘉实医药健 康股票A（005303）退出十 ...

Company Overview - Yinos Bio is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, primarily as a Contract Research Organization (CRO) [1] - The company's revenue composition is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Stock Performance - As of December 18, Yinos Bio's stock price increased by 2.03%, reaching 51.36 CNY per share, with a total market capitalization of 7.241 billion CNY [1] - Year-to-date, the stock price has risen by 45.95%, with a 19.16% increase over the last five trading days, a 10.64% increase over the last 20 days, and a 9.63% increase over the last 60 days [1] Financial Performance - For the period from January to September 2025, Yinos Bio reported a revenue of 571 million CNY, representing a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.7881 million CNY, a decline of 111.14% compared to the previous year [2] Shareholder Information - As of September 30, the number of shareholders for Yinos Bio was 4,849, a decrease of 9.97% from the previous period. The average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.1135 million CNY in dividends since its A-share listing [3] - Notable changes in institutional holdings include new entries from Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund among the top ten circulating shareholders [3]

Core Viewpoint - Shanghai Yinos Biotechnology Co., Ltd. has been awarded the "2025 Most Socially Responsible Listed Company Award" for its outstanding practices in social responsibility and professional service capabilities, highlighting its deep accumulation and core value in the CRO professional segment [1][3] Company Overview - Yinos is a comprehensive R&D service (CRO) company specializing in non-clinical research services for biomedicine, adhering to the core values of "science-led, quality-first, integrity, and win-win cooperation" [3] - The company focuses on major national biomedicine development needs and plays a significant role in drug evaluation services, contributing to the high-quality development of the biomedicine industry [3] Business Performance - In Q3 2025, Yinos achieved operating revenue of 195 million yuan, a quarter-on-quarter increase of 17.71%, maintaining a steady growth trend [4] - The company saw a 29.37% year-on-year increase in new order amounts, with significant growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA), which rose by 30.71% and 23.06% respectively [4] Market Position and Strategy - Yinos is positioned as a leading enterprise in the CRO industry, benefiting from a high-growth cycle and possessing technical advantages that meet high-end demand across the entire service chain [4] - The company has established a non-clinical drug metabolism platform compliant with ICH, FDA, and NMPA standards, enhancing its capabilities in radiolabeled isotopes and imaging evaluation research [4] Innovation and International Expansion - Yinos is continuously advancing frontier technologies, particularly in small nucleic acid drugs and CAR-T cell therapy, establishing a comprehensive technical service matrix [5][6] - The company has expanded its international market presence, with significant growth in new order amounts from overseas, enhancing its brand influence and recognition [6] Future Outlook - The award received is not only a recognition of past achievements but also an expectation for future development, as CRO companies play an increasingly important role in new drug development [6] - Yinos aims to leverage this award to strengthen its professional advantages while actively fulfilling social responsibilities, contributing to the high-quality development of China's biomedicine industry [6]

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in both revenue and net profit, indicating potential challenges in its business performance [2] - As of November 20, Yinosh's stock price increased by 0.69%, with a trading volume of 57.54 million yuan, while the net financing buy was negative at -397,600 yuan [1] - The financing balance of Yinosh is 59.99 million yuan, which accounts for 1.43% of its market capitalization, indicating a low level compared to the past year [1] Group 2 - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% [2] - The number of shareholders decreased by 9.97% to 4,849, while the average circulating shares per person increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten circulating shareholders list [2]

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a year-to-date increase of 28.73% but a recent decline of 9.40% over the past five trading days, indicating volatility in investor sentiment and market conditions [1]. Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1]. - The company was listed on September 3, 2024, and operates primarily in the medical biology sector, focusing on medical research outsourcing [1]. Financial Performance - As of September 30, 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.79 million yuan, reflecting a significant decline of 111.14% compared to the previous period [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3].

Core Viewpoint - Yinos's stock price has experienced fluctuations, with a year-to-date increase of 32.48% but a recent decline of 7.04% over the past five trading days [1] Group 1: Stock Performance - As of November 18, Yinos's stock price was 46.62 CNY per share, with a market capitalization of 6.572 billion CNY [1] - The stock has seen a trading volume of 16.86 million CNY and a turnover rate of 0.39% [1] - The stock's performance over various periods includes a 11.13% increase over the last 20 days and a 6.17% increase over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Yinos reported a revenue of 571 million CNY, reflecting a year-on-year decrease of 35.33% [2] - The company recorded a net profit attributable to shareholders of -14.79 million CNY, a decline of 111.14% year-on-year [2] - Cumulative cash dividends paid since the A-share listing amount to 45.11 million CNY [2] Group 3: Shareholder Information - As of September 30, 2025, the number of Yinos's shareholders was 4,849, a decrease of 9.97% from the previous period [2] - The average number of circulating shares per shareholder increased by 257.28% to 18,703 shares [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten shareholders list [2]

Core Insights - Yinosh experienced a decline of 2.28% on November 17, with a trading volume of 41.92 million yuan [1] - The company reported a financing net buy of -770,200 yuan on the same day, indicating a negative sentiment among investors [1] - As of November 17, the total margin balance for Yinosh was 61.27 million yuan, which is 1.42% of its market capitalization, reflecting a low financing level compared to the past year [1] Financial Performance - For the period from January to September 2025, Yinosh achieved a revenue of 571 million yuan, representing a year-on-year decrease of 35.33% [2] - The company reported a net profit attributable to shareholders of -14.79 million yuan, a significant decline of 111.14% compared to the previous year [2] Shareholder and Institutional Holdings - As of September 30, 2025, the number of Yinosh shareholders decreased by 9.97% to 4,849, while the average circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3]

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a current price of 47.70 CNY per share, reflecting a year-to-date increase of 35.55% and a recent decline of 2.03% on November 17 [1] Group 1: Financial Performance - For the period from January to September 2025, Yinosh reported a revenue of 571 million CNY, representing a year-on-year decrease of 35.33% [2] - The company recorded a net profit attributable to shareholders of -14.79 million CNY, a significant decline of 111.14% compared to the previous year [2] - Cumulative cash dividends paid by Yinosh since its A-share listing amount to 45.11 million CNY [3] Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of Yinosh shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - Major shareholders include new entrants such as Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which hold 1.12 million shares and 0.93 million shares respectively [3] - The stock's trading activity shows a net outflow of 628,300 CNY from main funds, with large orders accounting for 13.39% of purchases and 18.12% of sales [1]

Core Viewpoint - Yinosh's stock price has shown significant volatility, with a year-to-date increase of 39.24% and a recent decline of 2.00% on November 14, 2023, indicating potential market fluctuations and investor sentiment [1]. Group 1: Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010, with its listing date set for September 3, 2024 [1]. - The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1]. Group 2: Financial Performance - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, representing a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% compared to the previous year [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - Notable changes in institutional holdings include new entries from Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund among the top ten circulating shareholders [3].

Core Insights - Yinosh experienced a stock price increase of 10.46% on November 11, with a trading volume of 163 million yuan [1] - The company reported a significant decline in revenue and net profit for the first nine months of 2025, with revenue of 571 million yuan, down 35.33% year-on-year, and a net loss of 14.79 million yuan, a decrease of 111.14% [2] Financing and Trading Activity - On November 11, Yinosh had a financing buy-in amount of 10.01 million yuan and a net financing outflow of 5.66 million yuan, with a total financing balance of 63.92 million yuan, representing 1.41% of its market capitalization [1] - The financing balance is below the 20th percentile of the past year, indicating a low level of financing activity [1] - There were no short sales or repayments on November 11, with the short selling balance at zero, which is at the 90th percentile of the past year, indicating a high level of short selling activity [1] Shareholder and Institutional Holdings - As of September 30, the number of shareholders for Yinosh decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten circulating shareholders list [3]